Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field

Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.

Executives fromTocagen Inc., CytomX Therapeutics Inc., Trillium Therapeutics Inc., Xencor Inc. and Poseida Therapeutics Inc. sat down with Scrip to discuss what it takes to get an immuno-oncology deal done, starting with technology that gives pharma something it doesn't have but needs to improve the efficacy and safety of existing immunotherapies.

Companies with technology ranging from monoclonal antibodies to chimeric antigen receptor T cell (CAR-T) therapies assembled for the discussion last...